MedTrace Logo

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

NCT04274426 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.

Conditions

  • Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Interventions

DRUG

Carboplatin

Carboplatin will administered by intravenous route

DRUG

Pegylated liposomal doxorubicin (PLD)

PLD will be administered by intravenous route

DRUG

Gemcitabine

Gemcitabine will be administered by intravenous route

DRUG

Paclitaxel

Paclitaxel will be administered by intravenous route

DRUG

Mirvetuximab Soravtansine

Mirvetuximab Soravtansine will be administered by intravenous route

Sponsors & Collaborators

  • AGO Research GmbH

    lead INDUSTRY

Principal Investigators

  • Philipp Harter · Evangelische Kliniken Essen-Mitte, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-13
Primary Completion
2025-12-03
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274426 on ClinicalTrials.gov